Form 4: Alumis CFO John Schroer Granted Significant Equity Awards

Alumis Inc.'s Chief Financial Officer, John R. Schroer, was granted 28,000 restricted stock units and options to purchase 111,950 shares of common stock, effective July 29, 2025.

Summary

• Alumis Inc. Chief Financial Officer John R. Schroer was granted 28,000 shares of common stock as Restricted Stock Units (RSUs) and stock options to acquire 111,950 shares of common stock.
• The RSU grant, with a transaction date of July 29, 2025, has a vesting schedule where 25% of the shares vest on August 1, 2026, and the remaining shares vest in equal quarterly installments over the subsequent 12 quarters.
• The stock option grant, also dated July 29, 2025, has an exercise price of $3.95 per share and an expiration date of July 28, 2035.
• The vesting schedule for the stock options includes 25% vesting on July 29, 2026, with the remaining shares vesting in equal monthly installments over the following 36 months.
• Both grants are subject to Mr. Schroer's continuous service to Alumis Inc. as defined in the Issuer's 2024 Equity Incentive Plan.

Sentiment

Score: 7

Explanation: The grant of significant equity awards to a key executive like the CFO is generally a positive signal, indicating retention efforts and alignment of interests with long-term company performance. It's a standard compensation practice.

Positives

• The grants of 28,000 Restricted Stock Units and 111,950 stock options align the Chief Financial Officer's interests with long-term shareholder value.
• The equity awards serve as a significant component of executive compensation, incentivizing continued performance and retention.

Future Outlook

The grants are structured with future vesting dates extending through 2026 and beyond, indicating a long-term commitment to the Chief Financial Officer's continuous service and alignment with future company performance.

Industry Context

Equity grants to executive officers are a standard practice in the biotechnology and pharmaceutical industries, like Alumis Inc., to attract, retain, and incentivize key talent, aligning their interests with long-term company growth and shareholder value.

Comparison to Industry Standards

• Equity compensation packages, including RSUs and stock options, are common in the biotech sector for executive retention and performance incentives. The specific size and vesting schedules of these grants would typically be benchmarked against peer companies of similar size and stage of development, though this filing does not provide such comparative data.

Corporate Governance

Related Party Transactions

• The equity grants are transactions between the company and its Chief Financial Officer, which are considered related-party transactions in the context of executive compensation. These are standard compensation practices and are disclosed as required by SEC regulations.

Stakeholder Impact

• Shareholders: Potential for future dilution from the exercise of options and settlement of RSUs, but also alignment of executive incentives with shareholder value creation.
• Employees: May signal stability in executive leadership and a commitment to long-term growth.
• Management: The grants provide significant long-term compensation and retention incentives for the Chief Financial Officer.

Next Steps

• Vesting of 25% of stock options on July 29, 2026.
• Vesting of 25% of Restricted Stock Units on August 1, 2026.
• Subsequent quarterly vesting of remaining RSUs over 12 quarters.
• Subsequent monthly vesting of remaining stock options over 36 months.

Key Dates

Keywords

Alumis Inc., ALMS, John R. Schroer, Chief Financial Officer, CFO, Restricted Stock Units, RSU, Stock Options, Equity Grant, Insider Transaction, SEC Form 4, Executive Compensation, Vesting Schedule